Resveratrol augments paclitaxel sensitivity by modulating miR‐671‐5p/STOML2/PINK1/Parkin‐mediated autophagy signaling in A549 cell
Authors:
- 16 October 2023
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 38 (1) , e23557
Abstract
Background: Paclitaxel (PTX) resistance has become a notable clinical concern of Non‐small cell lung cancer (NSCLC). Our study aim is to investigate the effects of Resveratrol (RES) on NSCLC cells that have developed resistance to PTX. The NSCLC cell line A549 was employed in this investigation to establish a PTX‐resistant NSCLC cell line, denoted as A549/PTX, and established tumor transplantaton model. The presence of miR‐671‐5p, Stomatin‐like protein 2 (STOML2), and mitophagy biomarkers was evaluated using quantitative teal‐time PCR (qRT‐PCR) and western blot, The assessment of cell proliferation and apoptosis was conducted through the utilisation of colony formation and flow cytometry assays. The investigation of mitochondrial autolysosomes was conducted using transmission electron microscopy (TEM). Our results showed that the application of RES therapy resulted in a substantial improvement in the sansitivity of A549/PTX cells. RES exhibited an augmentation of apoptosis and a suppression of mitophagy in A549/PTX cells. RES induced an upregulation in the expression of miR‐671‐5p. This, in turn, leaded to the inhibition of STOML2, a protein that directly interacts with PINK1. In summary, our research indicates that RES improved the susceptibility of A549/PTX cells to PTX through miR‐671‐5p‐mediated STOML2 inhibition.Keywords
This publication has 36 references indexed in Scilit:
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Non-small-cell lung cancers: a heterogeneous set of diseasesNature Reviews Cancer, 2014
- Synergistic antitumor activity of resveratrol and miR-200c in human lung cancerOncology Reports, 2014
- Inhibition of Breast Cancer Metastasis by Resveratrol-Mediated Inactivation of Tumor-Evoked Regulatory B CellsThe Journal of Immunology, 2013
- A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myelomaBritish Journal of Haematology, 2012
- A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancerLung Cancer, 2012
- Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and PharmacodynamicsCancer Prevention Research, 2011
- Stomatin-like Protein 2 Is Overexpressed in Cancer and Involved in Regulating Cell Growth and Cell Adhesion in Human Esophageal Squamous Cell CarcinomaClinical Cancer Research, 2006
- Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1α and VEGF expression in human tongue squamous cell carcinoma and hepatoma cellsMolecular Cancer Therapeutics, 2005
- Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from GrapesScience, 1997